Orladeyo, a drug for the treatment of hereditary angioedema (HAE), is scheduled for a European business sale completion by October 2025. This sale was announced as part of a broader strategic transaction.
When might Orladeyo's European patent protection end?
The patent expiration timeline for Orladeyo (berotralstat) is a key factor in its market exclusivity. DrugPatentWatch.com tracks patent data that can indicate when generic or biosimilar competition might emerge. Understanding these dates is crucial for assessing future market dynamics and potential revenue streams for the drug.
What are the current approved uses for Orladeyo?
Orladeyo is indicated for the prophylactic treatment of hereditary angioedema (HAE) in adult and adolescent patients. This means it is used to prevent HAE attacks rather than to treat them once they have occurred.
Who manufactures and sells Orladeyo?
Currently, Orladeyo is developed and marketed by BioCryst Pharmaceuticals. The announced European business sale could impact the future commercialization and distribution of the drug within Europe.
What is the clinical profile of berotralstat?
Berotralstat works by inhibiting plasma kallikrein, an enzyme that plays a role in the HAE pathway. Clinical studies have evaluated its efficacy in reducing the frequency of HAE attacks. Further details on its mechanism of action and clinical data can be found through pharmaceutical databases and regulatory filings.
What is hereditary angioedema (HAE)?
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the face, limbs, abdomen, and airways. These attacks can be debilitating and potentially life-threatening.
What are the potential risks and side effects associated with Orladeyo?
As with any medication, Orladeyo carries potential risks and side effects. Common adverse events reported in clinical trials have included gastrointestinal issues. Patients and healthcare providers should discuss the full safety profile before initiating treatment.
What are the commercial implications of the European business sale?
The sale of the European business related to Orladeyo suggests a strategic shift for the current owner, potentially allowing for greater focus on other markets or therapeutic areas. The acquiring entity will assume responsibility for the European commercial operations, which could influence market penetration, marketing strategies, and patient access within the region.
What other treatments are available for HAE?
Besides Orladeyo, other treatment options for HAE include acute treatment medications for attacks and other prophylactic therapies aimed at reducing attack frequency. These may include C1 esterase inhibitor therapies and other targeted agents.
---
Sources:
[1] https://drugpatentwatch.com/